The best thing investors can take from these types of reports is the information provided to us about the target market we are entering.
It gives us an understanding of what the two majors have paid and what they have compared to what admedus is making.
There are clear differences and clear advantages
News: AHZ Admedus Says Cardiocel 3D And Vascucel Receives European Regulatory Approval, page-407
-
- There are more pages in this discussion • 161 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.14 |
Change
0.140(1.08%) |
Mkt cap ! $277.7M | |||
| Open | High | Low | Value | Volume |
| $13.20 | $13.50 | $13.14 | $559.5K | 42.05K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1180 | $13.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.35 | 500 | 1 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |